Loading...
XNAS
KRMD
Market cap147mUSD
Jun 12, Last price  
3.20USD
1D
0.00%
1Q
15.52%
Jan 2017
540.00%
Name

KORU Medical Systems Inc (Pre-Reincorp)

Chart & Performance

D1W1MN
XNAS:KRMD chart
P/E
—
P/S
4.39
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.24%
Rev. gr., 5y
7.75%
Revenues
34m
+17.98%
1,745,8061,734,5792,347,6783,439,1103,774,8734,920,7236,390,5347,763,9538,698,85211,244,66012,247,33812,293,65515,976,67217,353,73723,162,62124,176,44823,490,17527,896,03728,517,66633,646,463
Net income
-6m
L-55.85%
-217,815-254,721-2,4991,030,855889,444704,085815,893725,763703,429753,117782,864-534,9991,085,948910,570564,349-1,212,063-4,562,823-8,661,142-13,741,062-6,066,633
CFO
-320k
L-93.47%
-138,748-85,591117,614528,180382,2981,028,465560,601784,790954,388826,0991,914,813-331,616899,9121,479,662320,620-743,323-4,319,510-5,404,549-4,892,553-319,718

Profile

KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
URL
http://www.repro-med.com/
IPO date
Oct 27, 1993
Employees
85
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑022016‑02
Income
Revenues
33,646
17.98%
28,518
2.23%
27,896
18.76%
Cost of revenue
17,573
17,552
17,483
Unusual Expense (Income)
NOPBT
16,074
10,966
10,413
NOPBT Margin
47.77%
38.45%
37.33%
Operating Taxes
(3)
3,967
(2,014)
Tax Rate
36.18%
NOPAT
16,077
6,999
12,427
Net income
(6,067)
-55.85%
(13,741)
58.65%
(8,661)
89.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
446
407
BB yield
-0.40%
-0.25%
Debt
Debt current
516
792
877
Long-term debt
6,922
7,784
8,539
Deferred revenue
Other long-term liabilities
Net debt
(2,143)
(2,906)
(7,992)
Cash flow
Cash from operating activities
(320)
(4,893)
(5,405)
CAPEX
(1,297)
(783)
(2,802)
Cash from investing activities
(1,333)
(815)
(2,802)
Cash from financing activities
(249)
(219)
279
FCF
18,418
8,521
7,442
Balance
Cash
9,581
11,482
17,408
Long term investments
Excess cash
7,899
10,056
16,013
Stockholders' equity
(28,885)
(22,821)
(9,083)
Invested Capital
49,418
47,620
45,334
ROIC
33.14%
15.06%
29.99%
ROCE
78.29%
44.22%
28.72%
EV
Common stock shares outstanding
45,803
45,601
45,002
Price
3.85
56.82%
2.46
-31.23%
3.57
19.00%
Market cap
176,340
57.52%
111,951
-30.32%
160,657
20.65%
EV
174,197
109,045
152,666
EBITDA
16,962
11,836
11,000
EV/EBITDA
10.27
9.21
13.88
Interest
Interest/NOPBT